Differences between angiotensin-converting enzyme inhibition and angiotensin II-AT(1) antagonism on angiotensin-mediated responses in human internal mammary arteries

Voors, AA., Oosterga, M., Buikema, H., Mariani, M., Grandjean, JG. & van Glist, WH., Feb-2003, In : Journal of Cardiovascular Pharmacology. 41, 2, p. 178-184 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

The cur-rent study aimed to demonstrate differences between angiotensin (Ang)-converting enzyme (ACE) inhibition and Ang II-AT(1) receptor antagonism on full concentration-contraction responses to Ang I. Contraction responses to increasing concentrations of Ang I (1 nM-1 muM) were evaluated in organ baths in the presence of captopril (10 muM-1 MM) with or without a chymase inhibitor (1 muM soybean trypsin inhibitor), or irbesartan (0.1 nM-muM), in internal mammary arteries from 25 patients undergoing coronary bypass surgery. Responses were expressed as a percentage of the control response to 10 muM phenylephrine. Captopril did not change the maximum response to Ang I (control: 46.3 +/- 6.3%, captopril: 43.0 +/- 4.6%). In contrast, 0.1 muM irbesartan completely blocked the maximum response to Ang I (from 45.8 +/- 6.7% to 1.9 +/- 1.9%, p <0.001). However, addition of soybean trypsin inhibitor to captopril more effectively shifted -log pD(2) than captopril alone (0.47 +/- 0.06 vs 0.95 +/- 0.14 log units, p = 0.007). Ang I-mediated effects are much more effectively inhibited by Ang II antagonism than by ACE inhibition. The incomplete effects of captopril on the inhibition of Ang II formation might be caused by alternative Ang II forming enzyme(s), as was demonstrated by the additive effects of soybean trypsin inhibitor added to captopril.

Original languageEnglish
Pages (from-to)178-184
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Issue number2
Publication statusPublished - Feb-2003


  • angiotensin, contractile function, renin-angiotensin system, vasoactive agents, vasoconstriction/dilatation, CONGESTIVE-HEART-FAILURE, II FORMATION, SAPHENOUS-VEIN, PATHWAY, ACTIVATION, EXERCISE, RECEPTOR, THERAPY

ID: 4072625